Editas Medicine Inc

NASDAQ: EDIT
$5.63
-$0.20 (-3.4%)
Closing price May 24, 2024

EDIT Chart and Intraday Price

EDIT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 11 HURLEY ST., CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 860.02M USD
Shares Outstanding 81,674,000
Editas Medicine Inc is at the forefront of genome editing, pioneering treatments for serious diseases using CRISPR technology. With a focus on developing genomic medicines, its leading projects include EDIT-101 for a rare eye disease and reni-cel for sickle cell disease and beta-thalassemia. The company also explores cancer treatments through engineered T cells. Founded in 2013 and based in Cambridge, Massachusetts, Editas collaborates with industry leaders to advance its mission of transforming medicine.

EDIT Articles

Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Thursday's top analyst upgrades and downgrades included Albemarle, Arm, CrowdStrike, Dow, Fortinet, Hudson Pacific Properties, Lithium Americas, LyondellBasell Industries, Match, Palo Alto Networks,...
Monday's top analyst upgrades and downgrades included AbbVie, Adobe, Advance Auto Parts, Anheuser-Busch InBev, Bumble, Fortinet, Nike and Palo Alto Networks.
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk,...
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, American Eagle Outfitters, Azek, Bausch Health, Coinbase Global, Dell Technologies, Fidelity National Information...
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont and Salesforce.com.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Caesars Entertainment, Coinbase Global, Editas Medicine and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Bath & Body Works, Editas Medicine, GoDaddy, PetMed Express and Qorvo.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Domino’s Pizza, Editas Medicine, Roblox, Teva Pharmaceutical Industries and U.S. Steel.
Friday’s top analyst upgrades and downgrades included BP, Comcast, Coinbase, Cisco Systems, D.R. Horton, Editas Medicine, FuelCell, KB Home, Micron Technology, Splunk, United Airlines and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including BioCryst, Editas, Groupon, Sunrun, Twitter and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Airbnb, Centerpoint Energy, Editas Medicine and more.